Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021)

Lineage Cell Therapeutics (LCTX) reported Short term Debt of $523000.0 for Q1 2021, little changed quarter-over-quarter from $523000.0 in Q4 2020.

Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021) Analysis & Trends

Lineage Cell Therapeutics has reported Short term Debt for 4 years, with the latest figure at $523000.0 in Q1 2021.

For the quarter ending Q1 2021, Short term Debt changed N/A year-over-year to $523000.0; the trailing twelve-month figure through Mar 2021 stood at $523000.0 (changed N/A YoY), and the FY2020 full-year result was $523000.0, changed N/A from the prior year.
Short term Debt for Q1 2021 stood at $523000.0, roughly flat from $523000.0 in the prior quarter.
The five-year high for Short term Debt was $523000.0 in Q2 2020, with the low at $523000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Lineage Cell Therapeutics	303.84 Mn	239.94 Mn	1.73 Mn

Download Data